First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital

Mc, Ploy; Grelaud, C; Martin, Claude; Lumley, L. De; Denis, François

doi:10.1016/s0140-6736(05)79166-2

Cited by 289 publications

(157 citation statements)

References 3 publications

Supporting

Mentioning

147

Contrasting

Unclassified

Order By: Relevance

“…hVISA strains have been reported from a number of countries, and most of the isolates belonged to the New York/Japan MRSA clone (CDC, 1997;Hiramatsu et al, 1997a, b;Ploy et al, 1998). To date, five cases of hVISA infection have been detected in Hungary.…”

Section: Discussionmentioning

confidence: 99%

Phagocytosis and intracellular killing of heterogeneous vancomycin-intermediate Staphylococcus aureus strains

Méhes

Taskó

Székely

et al. 2012

Journal of Medical Microbiology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Phagocytosis and intracellular killing of heterogeneous vancomycin-intermediate Staphylococcus aureus strains

Méhes

Taskó

Székely

et al. 2012

Journal of Medical Microbiology

View full text Add to dashboard Cite

“…Prevalence of MRSA in hospitals increased from 2.1% in 1975 to 35% in 1991 [24] and it was 46% in Western Pacific region, 5.7% in Canada, varied from less than 2% in the Netherlands to 54.4% in Portugal, from 23.6% in Australia to more than 70% in Japan and Hong Kong [25] [26] and 30% -60% in Thailand [27]. For serious MRSA infections, vancomycin is the treatment of choice and MRSA strains with reduced susceptibility to vancomycin have been reported [28] [29] but in this study no vancomycin resistant isolates were found. Only 10% of S. pneumonia isolates were resistant to penicillin which might indicate that the resistance to this bacteria in particular was not very high.…”

Section: Discussionmentioning

confidence: 99%

Incidence of Antibiotic Resistance Bacteria in Jeddah's Ministry of Health Hospitals, Saudi Arabia

Halwani¹,

Tashkandy²,

Aly³

et al. 2015

AiM

View full text Add to dashboard Cite

This study aimed to determine the emergence and spread of resistant bacteria in Jeddah Ministry of Health hospitals. Sixteen month follow-up (January 2010 to April 2011) study was carried out and clinical isolates of hospitalized patients were collected, identified and their antimicrobial resistance was determined using two automated systems, Phoenix and Vitek 2. Results revealed that 6195 isolates were identified of which 94% (5846/6195) were Gram negatives. In Escherichia coli, the resistance was 40% ( M. A. Halwani et al.781

show abstract

“…La cepa MRSA aislada, denominada Mu50, tenía una CIM para vancomicina de 8 µg/ml determinada por microdilución en caldo. Desde entonces se han reportado cepas VISA en Europa (18,19), Estados Unidos (20)(21)(22)(23), Asia (24) y Brasil (25). El grupo colombiano de resistencia antimicrobiana, RESCOL (26), tras analizar 296 aislamientos nosocomiales de S.aureus en el período 2001-2002 encontró 52% de resistencia a meticilina, pero ninguna cepa VISA mediante la técnica de tamizaje en agar infusión cerebro corazón (BHIA, Brain-Heart infusion Agar) con 6 µg/ml de vancomicina según recomendación del CLSI y de los Centers for Disease Control (CDC) (27).…”

Section: Resistencia Intermedia a Vancomicina: Cepas Visaunclassified

Staphylococcus aureus resistente a vancomicina.

Rodríguez¹,

Vesga

2005

biomedica

View full text Add to dashboard Cite

Objetivo. Revisar la evolución y mecanismos moleculares de la resistencia de Staphylococcus aureus a vancomicina. Fuente de los datos. Se consultó la base de datos MEDLINE y se seleccionaron artículos tipo reportes de caso, estudios bioquímicos, de microscopía electrónica y biología molecular pertinentes. Síntesis. Después de casi 40 años de eficacia ininterrumpida de la vancomicina, en 1997 se reportaron los primeros casos de fracaso terapéutico debido a cepas de Staphylococcus aureus con resistencia intermedia, denominadas VISA (concentración inhibitoria mínima, CIM, 8 a 16 µg/ml), así como a cepas con resistencia heterogénea hVISA (CIM global = 4 µg/ml, pero con subpoblaciones VISA), en las cuales la resistencia está mediada por engrosamiento de la pared celular y disminución de su entrecruzamiento, lo que afecta la llegada del antibiótico al blanco principal, los monómeros del peptidoglicano en la membrana plasmática. En 2002 se aisló la primera de las 3 cepas reportadas hasta la fecha con resistencia total al antibiótico, denominadas VRSA (CIM>32 µg/ml), en las que se encontró el transposón Tn1546 proveniente de Enterococcus spp, responsable del reemplazo de la terminación D-Ala-D-Ala por D-Ala-Dlactato en los precursores de la pared celular con pérdida de la afinidad por el glicopéptido. Conclusiones. La resistencia a vancomicina es una realidad en S. aureus, mediada en el caso de VISA por alteraciones en la pared celular que atrapan el antibiótico antes de llegar al sitio de acción, y en el caso de VRSA, por transferencia desde Enterococcus spp. de genes que llevan a la modificación del blanco molecular.Palabras clave: Staphylococcus aureus, peptidoglicano, biosíntesis, antibióticos glicopéptidos, vancomicina, resistencia microbiana a drogas, resistencia a vancomicina. Vancomycin-resistant Staphylococcus aureusThe evolution and molecular mechanisms of vancomycin resistance in Staphylococcus aureus were reviewed. Case reports and research studies on biochemestry, electron microscopy and molecular biology of Staphylococcus aureus were selected from Medline database and summarized in the following review. After almost 40 years of successful treatment of S. aureus with vancomycin, several cases of clinical failures have been reported (since 1997). S. aureus strains have appeared with intermediate susceptibility (MIC 8-16 µg/ml), as well as strains with heterogeneous resistance (global MIC ≤ 4 µg/ml), but with subpopulations of intermediate susceptibility. In these cases, resistance is mediated by cell wall thickening with reduced cross linking. This traps the antibiotic before it reaches its major target, the murein monomers in the cell membrane. In 2002, a total vancomycin resistant strain (MIC ≥ 32 µg/ml) was reported with vanA genes from Enterococcus spp. These genes induce the change of D-Ala-D-Ala terminus for D-Ala-D-lactate in the cell wall precursors, leading to loss of affinity for glycopeptides. Vancomycin resistance in S. aureus has appeared; it is mediated by cell wall modifications that trap the ...

show abstract

First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital

Cited by 289 publications

References 3 publications

Phagocytosis and intracellular killing of heterogeneous vancomycin-intermediate Staphylococcus aureus strains

Phagocytosis and intracellular killing of heterogeneous vancomycin-intermediate Staphylococcus aureus strains

Incidence of Antibiotic Resistance Bacteria in Jeddah's Ministry of Health Hospitals, Saudi Arabia

Staphylococcus aureus resistente a vancomicina.

Contact Info

Product

Resources

About